Suppr超能文献

根据销售和索赔数据的国家抗菌药物监测的特点和局限性。

Characteristics and limitations of national antimicrobial surveillance according to sales and claims data.

机构信息

AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Collaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, Tohoku University, Sendai, Miyagi, Japan.

出版信息

PLoS One. 2021 May 11;16(5):e0251299. doi: 10.1371/journal.pone.0251299. eCollection 2021.

Abstract

PURPOSE

Antimicrobial use (AMU) is estimated at the national level by using sales data (S-AMU) or insurance claims data (C-AMU). However, these data might be biased by generic drugs that are not sold through wholesalers (direct sales) and therefore not recorded in sales databases, or by claims that are not submitted electronically and therefore not stored in claims databases. We evaluated these effects by comparing S-AMU and C-AMU to ascertain the characteristics and limitations of each kind of data. We also evaluated the interchangeability of these data by assessing their relationship.

METHODS

We calculated monthly defined daily doses per 1,000 inhabitants per day (DID) using sales and claims data from 2013 to 2017. To assess the effects of non-electronic claim submissions on C-AMU, we evaluated trends in the S-AMU/C-AMU ratio (SCR). To assess the effects of direct sales of S-AMU, we divided AMU into generic and branded drugs and evaluated each SCR in terms of oral versus parenteral drugs. To assess the relationship between S-AMU and C-AMU, we created a linear regression and evaluated its coefficient.

RESULTS

Median annual SCRs from 2013 to 2017 were 1.046, 0.993, 0.980, 0.987, and 0.967, respectively. SCRs dropped from 2013 to 2015, and then stabilized. Differences in SCRs between branded and generic drugs were significant for oral drugs (0.820 vs 1.079) but not parenteral drugs (1.200 vs 1.165), suggesting that direct sales of oral generic drugs were omitted in S-AMU. Coefficients of DID between S-AMU and C-AMU were high (generic, 0.90; branded, 0.84) in oral drugs but relatively low (generic, 0.32; branded, 0.52) in parenteral drugs.

CONCLUSIONS

The omission of direct sales information and non-electronically submitted claims have influenced S-AMU and C-AMU information, respectively. However, these data were well-correlated, and it is considered that both kinds of data are useful depending on the situation.

摘要

目的

通过使用销售数据(S-AMU)或保险索赔数据(C-AMU),在国家层面估计抗菌药物使用(AMU)。然而,这些数据可能会受到未通过批发商(直接销售)销售的通用药物的影响,因此未记录在销售数据库中,或者受到未以电子方式提交的索赔的影响,因此未存储在索赔数据库中。我们通过比较 S-AMU 和 C-AMU 来评估这些影响,以确定每种数据的特征和局限性。我们还通过评估它们之间的关系来评估这些数据的可互换性。

方法

我们使用 2013 年至 2017 年的销售和索赔数据,计算每千居民每天的定义日剂量(DID)。为了评估非电子索赔提交对 C-AMU 的影响,我们评估了 S-AMU/C-AMU 比值(SCR)的趋势。为了评估 S-AMU 直接销售的影响,我们将 AMU 分为通用药物和品牌药物,并评估了每种 SCR 与口服药物和注射药物的关系。为了评估 S-AMU 和 C-AMU 之间的关系,我们创建了一个线性回归,并评估了其系数。

结果

2013 年至 2017 年的年中值 SCR 分别为 1.046、0.993、0.980、0.987 和 0.967。SCR 从 2013 年到 2015 年下降,然后稳定下来。口服药物的品牌药物和通用药物的 SCR 差异有统计学意义(0.820 对 1.079),但注射药物的差异无统计学意义(1.200 对 1.165),这表明 S-AMU 中遗漏了口服通用药物的直接销售信息。S-AMU 和 C-AMU 之间 DID 的系数在口服药物中较高(通用药物,0.90;品牌药物,0.84),但在注射药物中相对较低(通用药物,0.32;品牌药物,0.52)。

结论

直接销售信息和非电子提交的索赔分别影响了 S-AMU 和 C-AMU 信息。然而,这些数据具有很好的相关性,并且认为根据情况这两种数据都是有用的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2541/8112693/7c99156ba2a9/pone.0251299.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验